Dr. Alisa Femia provides a recap of her conference presentation covering emerging treatments for cutaneous lupus. She notes that standard first-line management involves potent topical steroids, sun protection, and optimizing antimalarial regimens with agents like quinacrine or chloroquine. The discussion emphasizes the role of anifrolumab, an interferon receptor blocker that has demonstrated significant clinical benefits for skin disease. Additionally, she mentions other promising pipeline and off-label options, including deucravacitinib and a subcutaneous formulation of anifrolumab.